Canaccord Genuity Maintains Buy on Passage Bio, Maintains $13 Price Target
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and maintains $13 price target.
Canaccord Genuity analyst Whitney Ijem maintains Passage Bio (NASDAQ:PASG) with a Buy and maintains $13 price target.